Background: Pyrrolo[1,2-a][1,4]benzodiazepines (PBDs) have been described as a novel class of antifungal compounds with activity against dermatophytes and Aspergillus fumigatus. The initial structure-activity relationship showed that compounds with a chlorine substitution at position 7 have a higher activity compared with regioisomers or other substituents.
Introduction
Invasive fungal diseases, such as systemic aspergillosis, are associated with high morbidity and mortality and show a rising incidence that coincides with the increase in immunocompromised patients. 1 Also, non-fatal cutaneous fungal infections occur much more frequently and affect up to a quarter of the world population. 2 The growing importance of fungal diseases and the limitations of the existing drugs, i.e. the emergence of resistance, limited efficacy, drug -drug interactions and severe adverse effects, clearly highlight the need for new, safe and effective antifungals. Pyrrolo[1,2-a] [1, 4] benzodiazepines (PBDs) represent a novel class of compounds that showed promising activity against dermatophytes and Aspergillus fumigatus. 4 The initial structureactivity relationship (SAR) indicated that the compounds with a chlorine atom at position 7 performed better than their regioisomers with a chlorine atom at position 8, 9 or 10. Other substituents at position 7 (hydrogen, fluorine, methyl, thiomethyl and methoxy) were much less potent. Oxidation of the nitrogen atom in the diazepine ring enhanced the in vitro activity.
The present study further explored the SAR of PBDs with a chlorine atom at position 7 in a broad in vitro panel of clinically relevant dermatophytes, filamentous moulds and yeasts. The in 
Materials and methods
The compounds were synthesized and kindly supplied by Janssen, Beerse, Belgium. The in vitro susceptibility was profiled against a broad range of fungal species in accordance with the CLSI standard guidelines M27-A3 and M38-A2. 5, 6 To assess selectivity of inhibition, cytotoxicity was evaluated on human lung fibroblasts (MRC-5 SV 40 ). 1 Activity is expressed as the IC 50 value in mM, i.e. the concentration that results in a 50% growth inhibition compared with the untreated controls on the same test plate. For each compound -fungus combination, three independent replicates were analysed. The stock concentration of all compounds was 20 mM in DMSO. The final in-test concentration of DMSO was 0.5%. The in vivo efficacy of the oxidized PBDs was evaluated in an M. canis dermatitis model in guinea pigs. 7 Oral treatment started 2 h before infection and was continued for 5 consecutive days at 40 or 20 mg/kg. Topical treatment (1%, 0.25% or 0.06% formulations) started the day after infection and was applied twice daily for 4 days. Compounds were formulated in polyethylene glycol (PEG 200 ) for oral dosing and in a mixture of PEG 400 and PEG 1500 (3: 2 w: w) for topical treatment. Within each experiment, a vehicle-treated infected control group was included and itraconazole (oral administration of 20, 10, 5 and 2.5 mg/kg; topical administration of 1%, 0.25% and 0.06%) and terbinafine (oral administration of 10 mg/kg; topical administration of 1%) were included as reference antifungal controls. Each treatment was evaluated in three animals. Skin lesions were scored every 3 days for 3 weeks. The lesion scores were plotted over time and the maximal lesion score (MLS) and area under the curve (AUC) were determined as measures for lesion burden using GraphPad Prism version 4.01 (San Diego, CA, USA). The AUC and MLS of each treatment were expressed as percentages of the AUC or MLS obtained in the vehicle-treated infected control group. One-way ANOVA was used to identify significant activity (P ≤ 0.05). All experiments with animals were approved by the Animal Trials Ethics Committee of the University of Antwerp (Id. 2008 -14) and conducted in agreement with ethical standards. Table S1 (available as Supplementary data at JAC Online) shows the chemical structure of the PBDs and their in vitro activity profile against dermatophytes, filamentous moulds and yeasts. Several reference antifungals were included and showed IC 50 values in agreement with those found in the literature. 8 The dihydro-PBDs are designated A -L, whereas M -P represent the oxidized PBDs. Overall, PBDs showed good in vitro activity (IC 50 ,10 mM) against at least one of the fungal groups. All compounds were particularly active against dermatophytes, with IC 50 values in the low micromolar range. For example, Compound O showed IC 50 values of 0.6 mM against M. canis, 2.0 mM against Trichophyton mentagrophytes and 0.7 mM against Trichophyton rubrum, approaching or outperforming the activity of reference drug itraconazole against these dermatophytes (IC 50 values of 2.0, 0.4 and 0.6 mM, respectively). The potency against filamentous moulds was mainly seen for oxidized PBDs, which is in accordance with the initial SAR. 4 In particular, compounds with a CF 2 CH 3 -substitution showed activity against the Scedosporium species. The meta-substitutions of the oxidized PBDs appeared to be the most potent forms, while the para-substitutions were more active for the dihydro-PBDs. Candida parapsilosis proved to be the sole susceptible yeast species. No activity could be detected against other Candida spp., Fusarium spp., Rhizomucor spp., Rhizopus spp. and Sporothrix schenkii. Our results endorse and expand the previously reported PBD activity against the dermatophytes M. canis and Trichophyton spp., A. fumigatus and C. parapsilosis. None of the compounds showed significant cytotoxicity against MRC-5 cells and hence can be considered as highly selective.
Results and discussion
Because of the promising in vitro activity against M. canis (Table S1 ), the four oxidized PBDs (Compounds M, N, O and P) were dose-titrated in the guinea pig M. canis dermatitis model (Table 1) . In untreated controls, skin lesions develop by day 4, reach maximal severity by day 11 and then spontaneous healing starts. Almost full recovery is obtained by day 25 [ Figure 1 and Tables S2 and S3 (available In vitro and in vivo antifungal profiling of pyrrolobenzodiazepines control group, largely outperforming the reference drugs itraconazole and terbinafine (Table 1 and Figure 1 ).
In conclusion, PBDs with a chlorine atom at position 7 are very promising antifungal candidates with convincing in vitro and in vivo activity against dermatophytes. Compound O deserves further study in greater detail to explore its full potential in the treatment of dermatophytosis. In addition, PBDs with alternative substitution patterns should be investigated for their in vitro activity spectrum and in vivo potential in order to identify candidate compounds that comply with the target product profiles and address the need for new antifungal therapies. Paulussen et al.
